Mohamed Atta, MD
Nephrology · Baltimore, MDNPI 1417912262
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $42,263 of the $65,190 with a category attached, or 64.8%. 9 manufacturers reported payments, led by Amgen at 34.5% of the total. 2025 is the largest year on record at $26,300, more than ten times the $2,163 reported in 2019. Among nephrology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 81 payments — averaging $804.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$23K
- Alnylam Pharmaceuticals Inc.$22K
- Chiesi USA, Inc.$9K
- GSK$7K
- Calliditas Therapeutics US Inc.$3K
- Novartis$2K
- plus $643 from 3 others
Across 103 payments — averaging $9621.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$400K
- Novartis$182K
- Bayer$160K
- GSK$99K
- Alnylam Pharmaceuticals Inc.$47K
- E.r. Squibb & Sons, L.L.C.$46K
- plus $57K from 3 others
What the payments were for
- Consulting fees$42,26365%
- Speaking & faculty fees$14,40622%
- Travel & lodging$6,55210%
- Food & beverage$1,9513%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 30 | $22,507 |
| Alnylam Pharmaceuticals Inc. | 18 | $21,713 |
| Chiesi USA, Inc. | 4 | $9,073 |
| GSK | 10 | $6,601 |
| Calliditas Therapeutics US Inc. | 1 | $3,000 |
| Novartis | 8 | $1,652 |
| Eli Lilly | 1 | $500 |
| Bayer | 1 | $125 |
| Travere Therapeutics, Inc. | 8 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$65,190 in reported general payments places this provider in the 95th percentile of 285 nephrology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 67 | $61,593 |
| FarxigaDapagliflozin Propanediol | 54 | $49,003 |
| MounjaroTirzepatide | 13 | $13,411 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $8,976 |
| Nifedipine ErNifedipine | 43 | $859 |
| Losartan Potassium | 54 | $561 |
| Famotidine | 35 | $377 |
| Telmisartan | 20 | $301 |
| Ramipril | 11 | $180 |
| Amiloride Hcl | 15 | $166 |
| Carvedilol | 20 | $152 |
| Atorvastatin Calcium | 15 | $128 |
| Lisinopril | 12 | $120 |
| Tamsulosin Hcl | 13 | $101 |
| Prednisone | 19 | $94 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Baltimore
- Matthew WeirBaltimore$490K
- Chirag ParikhBaltimore$186K
- Mohamad HanounehBaltimore$174K
- Daniel BrennanBaltimore$133K
- Monika DhillonBaltimore$126K
- Duvuru GeethaBaltimore$91K
- Michelle EstrellaBaltimore$55K
- Zainab ObaidiBaltimore$39K
- Christopher SperatiBaltimore$37K
- Charlotte Jones BurtonBaltimore$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.